Benzinga · Nov 2, 2026
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $50 to $51.
NR
NASDAQ · NRXP
NRx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$2.28
Down-$0.16 (-6.56%)
Updated Nov 13, 2026, 11:57 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.94M
- P/E ratio
- -1.28
- Dividend yield
- 0.00%
- 52-week range
- $1.62 – $5.06
- Volume
- 605.05K
- Avg. volume
- 441.62K
Price performance · NRXP
NRXP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
NRXP closed at $2.28 after 21 trading sessions, down 15.87% for the selected period.
- Last close
- $2.28
- Period change
- -15.87%
- Period low
- $2.17
- Period high
- $2.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $2.43 | $2.44 | $2.25 | $2.28 | 605.05K |
| Nov 11, 2026 | $2.39 | $2.50 | $2.36 | $2.44 | 980.13K |
| Nov 10, 2026 | $2.32 | $2.40 | $2.29 | $2.36 | 497.77K |
| Nov 9, 2026 | $2.38 | $2.44 | $2.26 | $2.38 | 878.55K |
| Nov 6, 2026 | $2.30 | $2.40 | $2.26 | $2.38 | 604.42K |
| Nov 5, 2026 | $2.46 | $2.48 | $2.2406 | $2.27 | 832.74K |
| Nov 4, 2026 | $2.30 | $2.51 | $2.30 | $2.49 | 1.13M |
| Nov 3, 2026 | $2.165 | $2.34 | $2.11 | $2.24 | 1.8M |
| Nov 2, 2026 | $2.32 | $2.44 | $2.14 | $2.17 | 2.51M |
| Oct 30, 2026 | $2.83 | $2.84 | $2.11 | $2.27 | 15.64M |
| Oct 29, 2026 | $2.70 | $2.7732 | $2.615 | $2.66 | 1.76M |
| Oct 28, 2026 | $2.73 | $2.7449 | $2.64 | $2.69 | 834.66K |
| Oct 27, 2026 | $2.59 | $2.705 | $2.53 | $2.69 | 749.68K |
| Oct 26, 2026 | $2.48 | $2.59 | $2.459 | $2.55 | 594.73K |
| Oct 23, 2026 | $2.36 | $2.50 | $2.24 | $2.49 | 840.3K |
| Oct 22, 2026 | $2.57 | $2.6099 | $2.36 | $2.40 | 1.05M |
| Oct 21, 2026 | $2.65 | $2.70 | $2.61 | $2.63 | 526.55K |
| Oct 20, 2026 | $2.63 | $2.77 | $2.545 | $2.62 | 1.35M |
| Oct 19, 2026 | $2.815 | $2.815 | $2.6228 | $2.63 | 1.09M |
| Oct 16, 2026 | $2.70 | $2.76 | $2.572 | $2.60 | 1.23M |
| Oct 15, 2026 | $2.53 | $2.7718 | $2.48 | $2.71 | 1.18M |
Latest NRXP news
The latest Smart Investors Daily articles mentioning NRXP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NRXP research
Overview
Company profile and research snapshot.
Company profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | BTIG | Buy | — |
| Nov 2, 2026 | Ascendiant Capital | Buy | — |
| Oct 1, 2026 | Ascendiant Capital | Buy | — |
| Sep 14, 2026 | BTIG | Buy | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals (NASDAQ:NRXP) said the U.S. Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine injection, marking the company’s first approved product and its transition from a development-stage company to a commercial pharmaceutical company
SeekingAlpha · Oct 30, 2026
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine October 30, 2026 8:30 AM EDTCompany ParticipantsJonathan Javitt -...
Yahoo · Oct 30, 2026
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA. Current law requires preservatives and other inactive ingredients of drugs, foods, and cosmetics to be GRAS or demonstrated to be unsafe.Benzethonium Chloride is known to be toxic to the cells that line the body’s organs (epithelial cells) and is banned from new drugs, consumer
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
